Trial reportDiabetes technology & therapeutics2015
Multinight "bedside" closed-loop control for patients with type 1 diabetes.
Trial report in Diabetes technology & therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01939834 (Early Feasibility Study of Adaptive Advisory/Automated), which is not on this map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Efficacy and safety of closed-loop control system for type one diabetes in adolescents a meta analysis.Scientific reports · 2023Pooled it
- Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta-analysis of randomized-controlled trials.Journal of endocrinological investigation · 2022Pooled it
- Neural-Net Artificial Pancreas: A Randomized Crossover Trial of a First-in-Class Automated Insulin Delivery Algorithm.Diabetes technology & therapeutics · 2024Trial
- Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial.Diabetes technology & therapeutics · 2019Trial
- Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents.Pediatric diabetes · 2018Trial
- Overnight Closed-Loop Control Improves Glycemic Control in a Multicenter Study of Adults With Type 1 Diabetes.The Journal of clinical endocrinology and metabolism · 2017Trial
- Predictive Hyperglycemia and Hypoglycemia Minimization: In-Home Evaluation of Safety, Feasibility, and Efficacy in Overnight Glucose Control in Type 1 Diabetes.Diabetes care · 2017Trial
- Multinational Home Use of Closed-Loop Control Is Safe and Effective.Diabetes care · 2016Trial
- Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions.Journal of diabetes science and technology · 2016Trial
- An overview of the t:slim X2 and Mobi insulin pumps with Control-IQ technology: patient safety and device efficacy.Expert review of medical devices · 2025Review
- Early Stages of Automated Insulin Delivery.Journal of diabetes science and technology · 2025Review
- Early Stages of Automated Insulin Delivery.Diabetes technology & therapeutics · 2025Review
- Article
- Effectiveness and safety of a model predictive control (MPC) algorithm for an artificial pancreas system in outpatients with type 1 diabetes (T1D): systematic review and meta-analysis.Diabetology & metabolic syndrome · 2022Review
- Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.Endocrine reviews · 2019Review
- Diabetes Technology: Monitoring, Analytics, and Optimal Control.Cold Spring Harbor perspectives in medicine · 2019Review
- The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability.Diabetes technology & therapeutics · 2019Article
- Automated closed-loop control of diabetes: the artificial pancreas.Bioelectronic medicine · 2018Review
- Metrics for glycaemic control - from HbANature reviews. Endocrinology · 2017 · on this mapReview
- Coming of age: the artificial pancreas for type 1 diabetes.Diabetologia · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundStudies of closed-loop control (CLC) systems have improved glucose levels in patients with type 1 diabetes. In this study we test a new CLC concept aiming to "reset" the patient overnight to near-normoglycemia each morning, for several consecutive nights. SUBJECTS AND
methodsTen insulin pump users with type 1 diabetes (mean age, 46.4±8.5 years) were enrolled in a two-center (in the United States and Italy) randomized crossover trial comparing 5 consecutive nights of CLC (23:00-07:00 h) in an outpatient setting versus sensor-augmented insulin pump therapy of the same duration at home. Primary end points included time spent in 80-140 mg/dL as measured by continuous glucose monitoring overnight and fasting blood glucose distribution at 7:00 h.
resultsCompared with sensor-augmented pump therapy, CLC improved significantly time spent between 80 and 140 mg/dL (54.5% vs. 32.2%; P<0.001) and between 70 and 180 mg/dL (85.4% vs. 59.1%; P<0.001); CLC reduced the mean glucose level at 07:00 h (119.3 vs. 152.9 mg/dL; P<0.001) and overnight mean glucose level (139.0 vs. 170.3 mg/dL; P<0.001) using a marginally lower amount of insulin (6.1 vs. 6.8 units; P=0.1). Tighter overnight control led to improved daytime control on the next day: the overnight/next-day control correlation was r=0.52, P<0.01.
conclusionsMultinight CLC of insulin delivery (artificial pancreas) results in significant improvement in morning and overnight glucose levels and time in target range, with the potential to improve daytime control when glucose levels were "reset" to near-normoglycemia each morning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.